相关实验视频

Updated: Jun 10, 2025

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

胺β占主导地位阿尔茨海默氏病的神经病理变化

Gabor G Kovacs^1,2, Yuriko Katsumata^3,4, Xian Wu^3,4

¹Tanz Centre for Research in Neurodegenerative Disease and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5T 0S8, Canada.

Brain : a journal of neurology

|October 17, 2024

概括

阿尔茨海默病的神经病理变化 (ADNC) 亚型,特别是粉样β (Aβ) 主导的ADNC (AP-ADNC),表现出不同的临床和遗传特征. 这一发现对未来的阿尔茨海默氏症研究有影响.

科学领域:

神经病理学神经病理学
神经遗传学神经遗传学
阿尔茨海默氏症疾病研究研究

背景情况:

阿尔茨海默氏病的神经病理变化 (ADNC) 包含多种不同的病理特征.
一个子集,粉样β (Aβ) 主导的ADNC (AP-ADNC),具有丰富的Aβ斑块与最小的陶纠,表明独特的潜在机制.

研究的目的:

调查AP-ADNC与其他ADNC和初级年龄相关病症 (PART) 亚型相比,AP-ADNC的独特临床和遗传特征.
根据神经病理学发现对参与者的分层进行比较分析.

主要方法:

国家阿尔茨海默氏症协调中心 (NACC) 对1187名参与者的数据进行分析.
分为四组分层:AP-ADNC (n=95),低Braak PART (n=185),典型的ADNC (n=832) 和高Braak PART (n=75).这些组分为四组:AP-ADNC (n=95),低Braak PART (n=185),典型的ADNC (n=832) 和高Braak PART (n=75).
跨组的临床特征和遗传多态性 (APOE,SNX1,WNT3/MAPT,IGH) 的比较.

主要成果:

与典型的ADNC相比,AP-ADNC在某些临床特征上表现出显著的差异.
在APOE,SNX1,WNT3/MAPT和IGH基因中的AP-ADNC个体中发现了明显的遗传多态.
在分层的神经病理学组中观察到显著的差异.

结论:

粉样β (Aβ) 主导的ADNC (AP-ADNC) 是阿尔茨海默氏症神经病理变化的独特亚型.
这些发现凸显了ADNC内部的异质性,并表明了不同的病因路径.
在阿尔茨海默氏病研究中,AP-ADNC的独特概况对体内研究和治疗标识有重要意义.

关键词:

在ADGC中,ADGC是最重要的.在NACCC中,它是最重要的.粉样化物-β-β 的存在.生物标志物生物标志物扩散斑块是一种分散的斑块.

更多相关视频

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...